好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Elevated Neurofilament Light Chain and Oligoclonal Bands as Biomarkers of Autoimmune Encephalitis in Neuropsychiatric Systemic Lupus Erythematosus
Autoimmune Neurology
P1 - Poster Session 1 (12:00 PM-1:00 PM)
021

To characterize elevations in neurofilament light chain (NfL) and cerebrospinal fluid (CSF) oligoclonal bands (OCBs) as biomarkers of autoimmune encephalitis (AIE) in neuropsychiatric systemic lupus erythematosus (NPSLE).

Cognitive impairment is common among patients with systemic lupus erythematosus (SLE) and has numerous potential etiologies. Without reliable diagnostic biomarkers, it is difficult to ascertain which patients have NPSLE and may benefit from immunosuppression. We describe two patients with NPSLE manifesting as AIE with elevations in NfL (a marker of neuronal damage) and CSF-unique OCBs (markers of intrathecal immunoglobulin synthesis).

NA

Patient 1: A 38-year-old woman with mixed connective tissue disease, SLE and antiphospholipid antibody syndrome presented with subacute working memory deficits, disorganized thinking and paranoia, followed by paresthesias and tremors.

Patient 2: A 37-year-old woman with SLE and a remote history of viral encephalitis (fully recovered) presented with several months of working memory deficits, mood changes, falls and abnormal facial movements.

In both cases, brain MRIs with contrast were unrevealing. EEGs were slow or normal. CSF white blood cells (WBCs) and protein were normal in Patient 1, but slightly elevated in Patient 2 (WBCs 6/uL, protein 75 mg/dL). Serum and CSF inflammatory, autoimmune and infectious studies were negative, except for positive CSF-unique OCBs – 7 in Patient 1 and 10 in Patient 2 – and markedly elevated NfL – 412 pg/mL in Patient 1 and 131 pg/mL in Patient 2 (normal ≤ 11.4 pg/mL). Both patients were diagnosed with NPSLE manifesting as AIE. They were treated with intravenous corticosteroids, intravenous immunoglobulin and steroid-sparing agents (cyclophosphamide for Patient 1 and rituximab for Patient 2) with marked improvement.

Elevated NfL and CSF-unique OCBs may distinguish inflammatory causes of cognitive impairment in patients with SLE and identify those with NPSLE, even when brain MRIs are negative. These exploratory findings merit further evaluation in larger series.

Authors/Disclosures
Mattia Wruble, MD
PRESENTER
The institution of Dr. Wruble has received research support from Alexion. The institution of Dr. Wruble has received research support from Roche.
Philippe-Antoine Bilodeau, MD (Massachusetts General Hospital) Dr. Bilodeau has nothing to disclose.
Douglas R. Wilcox, MD, PhD (Massachusetts General Hospital) Dr. Wilcox has nothing to disclose.
Shamik Bhattacharyya, MD, FAAN (Brigham and Women's Hospital) Dr. Bhattacharyya has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NeuroLambda. Dr. Bhattacharyya has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals. Dr. Bhattacharyya has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Bhattacharyya has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Bhattacharyya has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Continuum. Dr. Bhattacharyya has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley. Dr. Bhattacharyya has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Merck. The institution of Dr. Bhattacharyya has received research support from Alexion Pharmaceuticals. The institution of Dr. Bhattacharyya has received research support from National Institute of Health. The institution of Dr. Bhattacharyya has received research support from UCB. The institution of Dr. Bhattacharyya has received research support from Genentech. Dr. Bhattacharyya has received publishing royalties from a publication relating to health care. Dr. Bhattacharyya has received publishing royalties from a publication relating to health care.